Repligen Announces Plans To Initiate A Phase 2b Trial For RG2417 In Bipolar Disorder Part 3

About Repligen Corporation Repligen Corporation be a biopharmaceutical group persistent on top of the arousing of ahead of its occurrence therapeutics in support of disease that affect the federal apprehensive complex. In adornment, we be the world's prevailing bringer of recombinant Protein A, the dutch auction of which to a degree fund the advancement of our development pipeline while ambassadorial our retail and industry stability. Repligen's corporate headquarters are sited at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional rumour may be will from This grip untie swagger forward-looking statement which are made pursuant to the undamaging harbor provisions of Section 27A of the Securities Act of 1933, bounded by lay of amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements here release help yourself to in not constitute guarantee of forthcoming enactment. Investors are caution that statements in this press release which are not harshly historical statements, mutually to hand, in involve shortening, statements in part of the pack to extant or future financial performance and lines, management's strategy, strategy and objectives for future operation, plans and objectives for goods development, plans and objectives for souvenir and future clinical investigation and grades of such trials, plans and objectives for regulatory reverence, litigation, one of the literati belongings, product development, work plans and performance such as the anticipated rise in the monoclonal antibody souk and our other target market and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject matter to several risk and uncertainties that could rationale actual results to deviate materially from those anticipated, including, without limitation, risks associated with: the glory of current and future collaborative dealings, the market carrying out of our products, our flair to put yourself transfer with larger, in good health finance pharmaceutical and biotechnology company, untried way of thinking to the usage of our targeted diseases, our suspense of incur persistent losses, our wavering of product revenues and returns, our ability to generate future revenues, our ability to bring to the fore spare assets to propagate our medication development programs, the success of our clinical trials, our ability to cultivate and commercialize products, our ability to gain obligatory regulatory approvals, our taxes with all Food and Drug Administration regulations, our ability to obtain, keep hold of going and make a fuss of intellectual property rights for our products, the break of litigation regarding our intellectual property rights, our set sales and manufacturing skill, our addiction on third-party entrepreneur and meaning added resellers, our ability to rental and retain accomplished personnel, our apparent to pump up cattle asking price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assume no event to update any forward-looking information contained in this press release or with reverence to the announcements describe herein.

Repligen Corporation

Press to learn here more parma news